Core Viewpoint - Zhenqu Technology has submitted its listing application to the Hong Kong Stock Exchange, with CITIC Securities and Guotai Junan as joint sponsors. The company focuses on electric vehicle (EV) control solutions and has developed a layered solution set that includes power modules, motor controllers, and power bricks, allowing customers to choose different levels of system integration [1] Group 1: Company Overview - Zhenqu Technology pioneered the concept of "power brick" and achieved mass production of the main drive power brick in 2021, significantly simplifying the assembly of control systems, enhancing platform reusability, and shortening development cycles [1] - The company has expanded its offerings to low-power controllers and domain controllers in the power domain and chassis domain [1] Group 2: Market Position and Achievements - As of September 30, 2025, the company has secured 50 design wins from 13 OEMs, with solutions applied to 82 vehicle models, 54 of which have entered mass production [1] - According to Frost & Sullivan, the company's rankings in the Chinese market by installation volume are as follows: - Motor controllers ranked 11th in 2024 and 8th in the first nine months of 2025 - Dual motor controllers ranked 3rd in the first nine months of 2025 - Main drive power bricks ranked 1st in 2024 and 2nd in the first nine months of 2025 - Power bricks installed in dual motor controllers ranked 1st in the first nine months of 2025 - Power modules ranked 8th in 2024 and 7th in the first nine months of 2025 [1] Group 3: Business Expansion - The company has leveraged its core technology to expand its business into emerging fields such as electric vertical takeoff and landing vehicles (eVTOL) and embodied intelligence [1]

核心临床阶段产品D-2570正在开展斑片状银屑病及溃疡性结肠炎（UC）的注册性III期临床试验，并计 划启动针对银屑病关节炎（PsA）、系统性红斑狼疮（SLE）及白癜风的额外临床试验。泰瑞司群为口 服选择性雌激素受体降解剂（SERD），正在开展ER+/HER2-乳腺癌的注册性III期临床试验。 全球及中国在肿瘤药物、靶向肿瘤药物、银屑病药物、UC药物及SERD药物市场均显示出显著的增长潜 力，例如中国靶向肿瘤药物市场预计到2035年将达到616亿美元。 截至2025年12月24日，公司已建立了全面且差异化的产品管线，包括两款商业化产品、两款临床阶段核 心产品、一款临床阶段候选产品及三个临床前候选产品。 已商业化产品中，贝福替尼（BPI-D0316）为自主研发的第三代EGFR酪氨酸激酶抑制剂，用于治疗 EGFR突变阳性的非小细胞肺癌（NSCLC），已在中国获批上市并纳入《国家医保药品目录》。格索雷 塞（D-1553）为自主研发的KRAS G12C抑制剂，是国内该靶点领域首个进入临床阶段的自研产品，已 在中国获批上市并纳入《国家医保药品目录》。公司已与正大天晴签署协议，授予其在中国内地开发、 注册、生产及商业化格 ...

Group 1 - The core viewpoint is that 2026 will be a crucial year for China's economic work, marking the beginning of the "15th Five-Year Plan" and the transition to a period of solid foundation and comprehensive efforts [1] - Analysts from ten major securities firms provide insights on market trends, industry allocations, and major investment opportunities for 2026, aiming to clarify the investment landscape for investors [1] Group 2 - CITIC Securities predicts that A-share company profit growth will show a trend of low growth initially followed by a recovery [2] - The market is expected to be influenced by the US-China trade agreement and the US midterm elections, with three phases of market performance anticipated [4] - Key investment themes include global pricing power in manufacturing, the expansion of Chinese companies overseas, the continuation of the tech trend with AI, and the potential recovery of domestic demand [4] Group 3 - CICC highlights that the restructuring of international order and China's industrial innovation will support A-share performance, with a market trend of initial growth followed by stabilization [5] - Analysts suggest focusing on growth sectors such as AI applications, industries benefiting from external demand, and cyclical sectors nearing recovery [7] Group 4 - GF Securities indicates that the A-share market is likely to maintain a "slow bull" pattern, with corporate profit structures undergoing significant changes [8][10] - The expected nominal GDP growth for China in 2026 is projected to reach 6.45%, significantly higher than in 2025, supporting the overall improvement in corporate profits [21] Group 5 - Analysts from various firms suggest that the market will shift from valuation-driven to profit-driven dynamics, with traditional and emerging industries contributing to profit recovery [15][17] - The focus on new production capabilities and the impact of policies like "anti-involution" are expected to improve competition in traditional industries and boost domestic demand [17] Group 6 - Analysts predict that more industries will enter a profit recovery phase in 2026, with nominal economic recovery and price increases being the most evident trends [18][20] - UBS forecasts that A-share company profit growth could rise to 8% due to improved nominal GDP growth and the narrowing of PPI declines [32] Group 7 - Analysts recommend focusing on four main investment themes: technological self-reliance, consumer sector recovery, "anti-involution" related sectors, and the global competitiveness of Chinese companies [34] - The market is expected to maintain a balanced style between growth and value, with cyclical sectors likely to outperform defensive sectors as the economy recovers [34]

中信证券裘翔：A股公司盈利增速将呈现前低后高态势 中信证券首席A股策略师裘翔认为，2026年A股公司盈利增速将呈现前低后高态势。 作者：许盈、孙翔峰、胡飞军、刘艺文、马静、王蕊 2026年是"十五五"规划开局之年，基本实现社会主义现代化这场接力跑，即将进入"夯实基础、全面发 力的关键时期"，做好经济工作至关重要。 为更全面展现市场机构对2026年经济形势、政策走向与投资布局的前瞻思考，证券时报·券商中国记者 特邀请十家券商首席策略分析师，围绕2026年市场趋势、行业板块配置思路、重大主题投资机会等发表 见解与展望，希望通过十大首席的专业视角，为投资者厘清脉络、把握机遇提供有力参考，共同助力资 本市场健康发展和国家现代化建设。 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 他分析，中美格局决定了行情节奏，行情可能将被中美签署贸易协议和美国中期选举分为三段：第一阶 段从当前到中美贸易协议落地前，市场上涨斜率预计放缓；第二阶段是协议落地到美国中期选举结束， A股有望在稳定的外部环境下迎来持续上涨；第三阶段是美国中期选举结束后，外部扰动的不确定性可 能会急剧提高，投资者需要把视野重心转回国 ...

作者：许盈、 孙翔峰、 胡飞军、 刘艺文、 马静、 王蕊 2026年是"十五五"规划开局之年，基本实现社会主义现代化这场接力跑，即将进入"夯实基础、全面发力的关键时期"，做好经济工作至关重要。 为更全面展现市场机构对2026年经济形势、政策走向与投资布局的前瞻思考，证券时报·券商中国记者特邀请十家券商首席策略分析师，围绕2026年市场趋势、行业 板块配置思路、重大主题投资机会等发表见解与展望，希望通过十大首席的专业视角，为投资者厘清脉络、把握机遇提供有力参考，共同助力资本市场健康发展和 国家现代化建设。 中信证券裘翔：A股公司盈利增速将呈现前低后高态势 中信证券首席A股策略师裘翔认为，2026年A股公司盈利增速将呈现前低后高态势。 他分析，中美格局决定了行情节奏，行情可能将被中美签署贸易协议和美国中期选举分为三段：第一阶段从当前到中美贸易协议落地前，市场上涨斜率预计放缓； 第二阶段是协议落地到美国中期选举结束，A股有望在稳定的外部环境下迎来持续上涨；第三阶段是美国中期选举结束后，外部扰动的不确定性可能会急剧提高， 投资者需要把视野重心转回国内。 裘翔认为，从主题投资机会和板块配置来看，四大线索值得重视：一是制 ...

Core Insights - The capital market showed a positive trend in 2025, with active trading reflected in the significant increase in transaction volume on the Longhu list, reaching 3.34 trillion yuan, a year-on-year growth of over 40% [1][2] - The competition among brokerage firms intensified, with notable changes in the rankings of the top 100 brokerage departments, highlighting the emergence of several "dark horse" firms [1][3] Group 1: Market Performance - In 2025, a total of 7,029 brokerage departments appeared on the Longhu list 123,900 times, with a total transaction volume of 3.34 trillion yuan, marking a 42.6% increase year-on-year [2] - The top 100 brokerage departments accounted for 2.26 trillion yuan of the total transaction volume, representing 67.66% of the market share, indicating a strong head effect [2] Group 2: Top Brokerage Departments - The "Lhasa team" under Dongfang Caifu Securities maintained a strong performance, occupying three of the top ten positions, with the Lhasa Tuanjie Road No. 1 Securities Department leading with a transaction volume of 127.87 billion yuan [2] - New entrants to the top ten include Kaiyuan Securities' Xi'an Xidajie Securities Department, which rose from 27th place in 2024 to 3rd in 2025, and several other firms that significantly improved their rankings [2][3] Group 3: Emerging Firms and Foreign Participation - Several "dark horse" brokerage departments made significant leaps in rankings, such as Guotai Junan's Shanghai Jing'an District New Zha Road Securities Department, which rose from 559th to 14th place [3] - The presence of foreign brokerage firms is increasing, with six foreign brokerage departments making it into the top 50, including UBS and Goldman Sachs, showcasing their growing influence in the market [4] Group 4: Industry Trends - The competition in brokerage business has intensified, reflecting differences in client scale, market share, and overall strength among various firms, as well as the strategic focus on regional development by branch offices [5] - The Longhu list serves as an important indicator of market sentiment and hotspots, with sectors like general equipment, chemical products, computer software, automotive, and semiconductors attracting significant investment [6]

关于部分控股股东及其一致行动人 进行质押式回购交易 展期的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ● 浙江华康药业股份有限公司（以下简称"公司"）部分控股股东及其一致行动人程新平先生、徐小荣先 生和余建明先生分别持有公司16,685,055股、15,691,337股、13,143,335股,分别占总股本的5.51%、 5.18%、4.34%。本次程新平先生、徐小荣先生和余建明先生将各自部分持有股份中的9,000,000股、 9,500,000股、7,000,000股质押给中信证券股份有限公司（以下简称"中信证券"），本次股份质押展期业 务完成后，其质押股份共计25,500,000股，占公司总股本8.41%。 一、上市公司股份质押 证券代码：605077 证券简称：华康股份 公告编号：2025-100 债券代码：111018 债券简称：华康转债 浙江华康药业股份有限公司 公司近日接到部分控股股东及其一致行动人程新平先生、徐小荣先生、余建明先生的通知，获悉上述人 员与中信证券办理了股票质押式回购 ...

中信证券首席A股策略师裘翔认为，2026年A股公司盈利增速将呈现前低后高态势。 裘翔认为，从主题投资机会和板块配置来看，四大线索值得重视：一是制造业争夺全球定价权，资源、 传统制造产业升级，把份额优势转化为定价权和利润率的持续抬升，可关注的重点大类行业包括有色、 化工和新能源；二是中企出海与全球化，大幅打开了市值天花板和利润增长空间，可重点关注大类行业 包括机械、创新药、电力设备、军工；三是科技行情延续，AI（人工智能）进一步拓展商用版图，延 续科技趋势并放大中企相对竞争优势，相关重点大类行业包括：半导体、算力、端侧硬件、AI应用； 四是关注内需的超预期修复机会，内需敞口品种景气度虽然一般，但也潜藏着较大的修复空间和估值弹 性。 （文章来源：证券时报） 他分析，中美格局决定了行情节奏，行情可能将被中美签署贸易协议和美国中期选举分为三段：第一阶 段从当前到中美贸易协议落地前，市场上涨斜率预计放缓；第二阶段是协议落地到美国中期选举结束， A股有望在稳定的外部环境下迎来持续上涨；第三阶段是美国中期选举结束后，外部扰动的不确定性可 能会急剧提高，投资者需要把视野重心转回国内。 ...

本报记者 于宏 随着我国资本市场高水平对外开放持续推进，外资券商在市场中也发挥着日益重要的作用，表现较为亮眼。2025年，有6 家外资券商营业部跻身龙虎榜营业部前50名。其中，瑞银证券旗下的上海花园石桥路证券营业部、上海浦东新区花园石桥路第 二证券营业部分别位列第8名、第27名，分别较2024年同期提升60名、94名。高盛（中国）上海浦东新区世纪大道证券营业 部、摩根大通（中国）上海银城中路证券营业部、东亚前海证券旗下的苏州分公司和上海分公司分别位列第9名、第23名、第 31名、第42名。 回顾刚刚过去的2025年，资本市场走势向好，交投活跃，这一态势鲜明反映在龙虎榜营业部成交额数据上。东方财富 Choice数据显示，2025年，龙虎榜营业部成交额达3.34万亿元，同比增长超40%。行情向好背景下，券商营业部的竞争也更加 激烈，龙虎榜营业部前100名（以下简称"百强营业部"）座次变动显著，多家"黑马"营业部排名实现大幅跃升。同时，分公司 和外资券商营业部日渐成为龙虎榜上不可忽视的力量。 另外，多家"黑马"营业部排名显著跃升。除上述一跃跻身前三的开源证券西安西大街证券营业部外，国泰海通上海静安区 新闸路证券营业 ...

【报告导读】 1. 行业龙头地位稳固，综合实力全面领跑。 2. 经营业绩稳中求进，盈利、风控能力双优。 3. 核心领域重点突破，增长潜力持续提升。 核心观点 行业龙头地位稳固，综合实力全面领跑：中信证券作为行业领军者，综合实力在资本规模、业务覆盖、品牌影响力等核心维度均实现全方位领先，龙头地 位根基深厚且持续巩固。公司依托大股东中信集团的强大资源禀赋，深度共享集团内银行、保险、信托等全金融牌照资源，同时借助集团全球产业布局与 客户网络，形成"金融+产业"的协同优势。公司管理层展现出行业顶尖的战略前瞻性，构建了"顺周期扩张增效、逆周期构筑壁垒"的发展路径，在行业周 期性波动中始终保持领先优势，成为行业内战略定力与执行效率的标杆企业。 经营业绩稳中求进，盈利、风控能力双优：公司作为国内率先实现总资产突破两万亿元的券商，绝对领先的资本实力与高效的资本运作能力，为业务边界 拓展、全球化布局及风险抵御筑牢核心根基。均衡多元的业务结构是公司穿越市场周期、维持业绩韧性的核心支撑，通过构建核心业务协同发展的格局， 各项主营业务收入规模大多稳居行业第一且优势显著。这一格局既充分彰显了公司的综合竞争实力，更构建起业绩增长的"多引 ...